BIO 201 - BiOneCure Therapeutics
Alternative Names: BIO-201 - BiOneCure TherapeuticsLatest Information Update: 08 Jul 2023
At a glance
- Originator BiOneCure Therapeutics
- Class Antineoplastics; Bispecific antibodies; Drug conjugates; Immunoconjugates
- Mechanism of Action DNA topoisomerase I inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 02 Jun 2023 Pharmacodynamics data from a preclinical X trial in solid tumours presented at the 59th Annual Meeting of the American Society of Clinical Oncology (ASCO-2023)
- 12 Apr 2022 Preclinical trials in Solid tumours in USA (Parenteral) on or before April 2022 (BiOneCure Therapeutics pipeline; April 2022)